Protalix BioTherapeutics, Inc. — Director's Dealing 2009

Aug 21, 2009

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protalix BioTherapeutics, Inc. (PLX)
CIK: 0001006281
Period of Report: 2009-08-20

Reporting Person: FROST PHILLIP MD ET AL (10% Owner)
Reporting Person: Frost Gamma Investments Trust (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2009-08-20	Common Stock	S	3458	$6.05	Disposed	8628455	Indirect
2009-08-20	Common Stock	S	31821	$6.07	Disposed	8596634	Indirect
2009-08-20	Common Stock	S	728	$6.08	Disposed	8595906	Indirect
2009-08-20	Common Stock	S	4550	$6.09	Disposed	8591356	Indirect
2009-08-20	Common Stock	S	46031	$6.10	Disposed	8545325	Indirect
2009-08-20	Common Stock	S	2859	$6.11	Disposed	8542466	Indirect
2009-08-20	Common Stock	S	91	$6.12	Disposed	8542375	Indirect
2009-08-20	Common Stock	S	4280	$6.14	Disposed	8538095	Indirect
2009-08-20	Common Stock	S	6182	$6.15	Disposed	8531913	Indirect
2009-08-21	Common Stock	S	700	$6.08	Disposed	8531213	Indirect
2009-08-21	Common Stock	S	12200	$6.09	Disposed	8519013	Indirect
2009-08-21	Common Stock	S	2100	$6.10	Disposed	8516913	Indirect

Footnotes

F1: These securities are held by Frost Gamma Investments Trust, of which the Reporting Person is the trustee. Frost Gamma
Limited Partnership is the sole and exclusive beneficiary of Frost Gamma Investments Trust. The Reporting Person is one of
two limited partners of Frost Gamma Limited Partnership. The general partner of Frost Gamma Limited Partnership is Frost
Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation, of which the Reporting Person is
the sole shareholder.